VEGFA and colorectal carcinoma: Among them, bevacizumab, an anti-VEGF-A mAb, approved by the FDA and EMA for the treatment of various cancers, including CRC and HCC, has shown an effect on VEGF-induced lymphangiogenesis in the cornea [81].